IPAC2019 - List of Authors (Neville, Z.S.)

Paper	Title	Page
THPMP052	Recent Progress in R&D for Ionetix Ion-12SC Superconducting Cyclotron for Production of Medical Isotopes	3568
	X. Wu, G.F. Blosser, G.S. Horner, Z.S. Neville, J.M. Paquette, N.R. Usher, J.J. Vincent Ionetix, Lansing, Michigan, USA D.M. Alt NSCL, East Lansing, Michigan, USA
	The Ion-12SC is a sub-compact, 12.5 MeV proton su-perconducting isochronous cyclotron for commercial medical isotope production recently developed at Ionetix Corporation [1]. The machine features a patented cold steel and cryogen-free conduction cooling magnet, a low power internal cold-cathode PIG ion source, and an inter-nal liquid target [2]. It was initially designed to produce N-13 ammonia for dose on-demand cardiology applica-tions but can also be used to produce F-18, Ga-68 and other medical isotopes widely used in Positron Emission Tomography (PET). The 1st engineering prototype was completed and commissioned in September 2015, and four additional units have been completed since [3]. The first two units have been installed and operated at the University of Michigan and MIT. R&D efforts in physics and engineering have continued to improve machine performance, stability and reliability. These improve-ments include: 1) Water cooling added to the dummy dee to limit the operating temperature of the ion source to improve lifetime and performance, 2) Magnetic field maps, obtained with a Hall probe based mapper, were used to accurately measure the isochronism and provide information needed to compensate for any unwanted 1st harmonics and 3) Feedback based control methods ap-plied to regulate the beam intensity on target by adjusting the ion source cathode current. The C1 unit installed at the University of Michigan Medical School early this year treated ~100 patients/month with N-13 ammonia. The machines are now capable of routinely producing > 21 doses/day with > 99% availability. The Ionetix manu-facturing facility is capable of producing up to 30 ma-chines per year.
DOI •	reference for this paper ※ https://doi.org/10.18429/JACoW-IPAC2019-THPMP052
About •	paper received ※ 14 May 2019 paper accepted ※ 22 May 2019 issue date ※ 21 June 2019
Export •	reference for this paper using ※ BibTeX, ※ LaTeX, ※ Text/Word, ※ RIS, ※ EndNote (xml)

Paper

Title

Page

Recent Progress in R&D for Ionetix Ion-12SC Superconducting Cyclotron for Production of Medical Isotopes

3568

X. Wu, G.F. Blosser, G.S. Horner, Z.S. Neville, J.M. Paquette, N.R. Usher, J.J. Vincent
Ionetix, Lansing, Michigan, USA
D.M. Alt
NSCL, East Lansing, Michigan, USA

The Ion-12SC is a sub-compact, 12.5 MeV proton su-perconducting isochronous cyclotron for commercial medical isotope production recently developed at Ionetix Corporation [1]. The machine features a patented cold steel and cryogen-free conduction cooling magnet, a low power internal cold-cathode PIG ion source, and an inter-nal liquid target [2]. It was initially designed to produce N-13 ammonia for dose on-demand cardiology applica-tions but can also be used to produce F-18, Ga-68 and other medical isotopes widely used in Positron Emission Tomography (PET). The 1st engineering prototype was completed and commissioned in September 2015, and four additional units have been completed since [3]. The first two units have been installed and operated at the University of Michigan and MIT. R&D efforts in physics and engineering have continued to improve machine performance, stability and reliability. These improve-ments include: 1) Water cooling added to the dummy dee to limit the operating temperature of the ion source to improve lifetime and performance, 2) Magnetic field maps, obtained with a Hall probe based mapper, were used to accurately measure the isochronism and provide information needed to compensate for any unwanted 1st harmonics and 3) Feedback based control methods ap-plied to regulate the beam intensity on target by adjusting the ion source cathode current. The C1 unit installed at the University of Michigan Medical School early this year treated ~100 patients/month with N-13 ammonia. The machines are now capable of routinely producing > 21 doses/day with > 99% availability. The Ionetix manu-facturing facility is capable of producing up to 30 ma-chines per year.

DOI •

reference for this paper ※ https://doi.org/10.18429/JACoW-IPAC2019-THPMP052

About •

paper received ※ 14 May 2019 paper accepted ※ 22 May 2019 issue date ※ 21 June 2019

Export •

reference for this paper using ※ BibTeX, ※ LaTeX, ※ Text/Word, ※ RIS, ※ EndNote (xml)